P

PeterLabs Holdings Bhd
KLSE:PLABS

Watchlist Manager
PeterLabs Holdings Bhd
KLSE:PLABS
Watchlist
Price: 0.175 MYR 2.94%
Market Cap: 48.2m MYR
Have any thoughts about
PeterLabs Holdings Bhd?
Write Note

Relative Value

The Relative Value of one PLABS stock under the Base Case scenario is 0.292 MYR. Compared to the current market price of 0.175 MYR, PeterLabs Holdings Bhd is Undervalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PLABS Relative Value
Base Case
0.292 MYR
Undervaluation 40%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
86
Median 3Y
0.3
Median 5Y
0.3
Industry
2.6
vs History
25
vs Industry
25
Median 3Y
14.5
Median 5Y
13.3
Industry
23
vs History
61
vs Industry
45
Median 3Y
9.3
Median 5Y
6.6
Industry
17.8
vs History
23
vs Industry
25
Median 3Y
-6
Median 5Y
4.1
Industry
25.4
vs History
84
vs Industry
66
Median 3Y
0.7
Median 5Y
0.7
Industry
2.2
vs History
92
vs Industry
89
Median 3Y
0.2
Median 5Y
0.3
Industry
2.8
vs History
77
vs Industry
69
Median 3Y
1.8
Median 5Y
1.8
Industry
5.4
vs History
34
vs Industry
37
Median 3Y
6.5
Median 5Y
5.4
Industry
13.7
vs History
34
vs Industry
40
Median 3Y
6.5
Median 5Y
5.4
Industry
17.2
vs History
63
vs Industry
47
Median 3Y
7.6
Median 5Y
5.4
Industry
16.5
vs History
4
vs Industry
27
Median 3Y
9.8
Median 5Y
6.4
Industry
19.3
vs History
92
vs Industry
72
Median 3Y
0.5
Median 5Y
0.5
Industry
2

Multiples Across Competitors

PLABS Competitors Multiples
PeterLabs Holdings Bhd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
MY
PeterLabs Holdings Bhd
KLSE:PLABS
48.2m MYR 0.3 14.1 5.4 5.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
746.8B USD 18.3 89.2 48 53.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
365.6B USD 4.2 24.9 12 15.7
US
Merck & Co Inc
NYSE:MRK
249.1B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.4B CHF 4.2 12.6 10 14.8
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.4 169.3 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
MY
P
PeterLabs Holdings Bhd
KLSE:PLABS
Average P/E: 30.7
14.1
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.2
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top